Aptus Capital Advisors LLC Purchases 16,594 Shares of Encompass Health Corporation $EHC

Aptus Capital Advisors LLC grew its stake in shares of Encompass Health Corporation (NYSE:EHC) by 15.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 126,149 shares of the company’s stock after acquiring an additional 16,594 shares during the quarter. Aptus Capital Advisors LLC’s holdings in Encompass Health were worth $16,023,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Citizens National Bank Trust Department purchased a new stake in Encompass Health in the third quarter worth approximately $26,000. First Horizon Corp purchased a new stake in Encompass Health during the third quarter valued at approximately $34,000. Westside Investment Management Inc. boosted its stake in shares of Encompass Health by 56.7% during the 3rd quarter. Westside Investment Management Inc. now owns 279 shares of the company’s stock worth $35,000 after acquiring an additional 101 shares during the last quarter. Assetmark Inc. grew its position in shares of Encompass Health by 88.1% during the 3rd quarter. Assetmark Inc. now owns 299 shares of the company’s stock valued at $38,000 after acquiring an additional 140 shares during the period. Finally, Root Financial Partners LLC bought a new position in Encompass Health in the 3rd quarter worth $39,000. Institutional investors own 97.25% of the company’s stock.

Encompass Health Stock Down 0.7%

Shares of NYSE EHC opened at $106.89 on Friday. Encompass Health Corporation has a 52-week low of $92.53 and a 52-week high of $127.99. The firm has a market capitalization of $10.63 billion, a price-to-earnings ratio of 19.29, a PEG ratio of 2.06 and a beta of 0.71. The stock has a 50 day moving average price of $103.93 and a 200 day moving average price of $113.71. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 1.08.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Thursday, February 5th. The company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.17. The company had revenue of $3.09 billion for the quarter, compared to analyst estimates of $1.54 billion. Encompass Health had a net margin of 9.54% and a return on equity of 18.20%. Encompass Health’s revenue was up 9.9% compared to the same quarter last year. During the same period last year, the company posted $1.17 earnings per share. Encompass Health has set its FY 2026 guidance at 5.810-6.100 EPS. Sell-side analysts expect that Encompass Health Corporation will post 4.8 earnings per share for the current year.

Encompass Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Wednesday, April 1st will be paid a $0.19 dividend. The ex-dividend date is Wednesday, April 1st. This represents a $0.76 dividend on an annualized basis and a yield of 0.7%. Encompass Health’s dividend payout ratio (DPR) is 13.72%.

Insider Buying and Selling at Encompass Health

In other news, CEO Mark J. Tarr sold 150,000 shares of the business’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $111.64, for a total transaction of $16,746,000.00. Following the sale, the chief executive officer owned 377,070 shares in the company, valued at approximately $42,096,094.80. The trade was a 28.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on EHC. Wall Street Zen upgraded Encompass Health from a “hold” rating to a “buy” rating in a research report on Sunday, January 18th. Barclays raised their price target on Encompass Health from $150.00 to $153.00 and gave the company an “overweight” rating in a report on Friday, February 6th. Finally, Zacks Research cut Encompass Health from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 19th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $143.29.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.